ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Alzheimers Dis Parkinsonism,

Prevention of Cognitive Loss by Using Thiamine Plus Either Fluoxetine or Pioglitazone

Jeffrey Fessel*
Department of Medicine, University of California, San Francisco, US
*Corresponding Author : Jeffrey Fessel, Department of Medicine, University of California, San Francisco, US, Tel: 415563 0818, Email: jeffreyfessel@gmail.com

Received Date: May 18, 2022 / Published Date: Jul 25, 2022

Abstract

The notion that a single event might be causative has hampered the search for either a preventative or cure for disturbed cognition. The cellular composition of the brain comprises five cell types: Neurons, microglia, astrocytes, oligodendrocytes and endothelial cells. Successful treatment, whether for prevention or cure of Alzheimer’s Dementia (AD), must address all cell types These cell types may interact with each other to form a complex system, with interdependence, synergy and adaptability; once that system has changed so as to create the emergence of Alzheimer’s Dementia (AD), it may be very difficult and perhaps impossible, to move it backwards to an earlier, preAD state. Therefore, prevention rather than cure should be the goal. Each of three available drugs acts to benefit all five cell types: Fluoxetine, pioglitazone and thiamine. This article describes the actions of each. Two of the drugs given together might be a powerful prophylactic against cognitive loss in persons at risk: Thiamine plus fluoxetine, thiamine plus pioglitazone or fluoxetine plus pioglitazone. Their potential benefit should be tested in a clinical trial.

Keywords: Alzheimer’s dementia; Interdependence; Pioglitazone; Synergy

Top